A new market research report by Transparency Market Research, titled “Hypersensitivity Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 – 2020,” presents a comprehensive evaluation of the market for hypersensitivity and throws light on the partnered and out-licensed product portfolio. The report also evaluates the growth potential of the market for hypersensitivity and its key areas of focus. The report aids in developing strategic initiatives by gathering information on prime areas of focus within the market for hypersensitivity and helps in exploiting the partnership and collaboration opportunities within the market. The snapshot of the global clinical trials landscape for hypersensitivity has also been included in this research report. The report also reviews the leading companies operating in the market for hypersensitivity.
Get Report Sample and Customization:
As stated in the report, hypersensitivity can result in a number of lifelong disorders, serious injuries, and can even prove to be fatal. These diseases include erythroblastosis fetalis, asthma, Goodpasture’s syndrome, myasthenia gravis, Graves' disease, systemic lupus erythematosus, and rheumatoid arthritis, among others. On the basis of type of hypersensitivity reaction, the market is segmented into delayed hypersensitivity and immediate hypersensitivity reaction. Amongst these, immediate reactions or allergic reactions comprise antibodies, while the segment of delayed hypersensitivity reactions comprises T lymphocytes. These can be further classified into type I – immediate hypersensitivity reaction involving IgE, type II – cytotoxic hypersensitivity reaction involving IgG and IgM, type III – immune-complex reaction involving circulation Ag-Ab (antigen-antibody) complex, and type IV – delayed hypersensitivity reactions involving T cells.
According to the report, drug hypersensitivity has become a chief concern in recent years. Due to hypersensitivity, an individual becomes allergic towards a drug or drugs. Such drugs include beta-lactams such as penicillin and insulin. The report states that diagnosis of allergies caused by hypersensitivity is carried out by utilizing numerous immune and molecular assays delivering accurate and quick test results. For instance, the ImmunoCAP test by Thermo Fisher Scientific is amongst the most broadly utilized tests used for allergy testing, as stated in the report. As per the report, the market for hypersensitivity includes a number of drugs for treating hypersensitivity reactions. Some of these drugs are celiprolol, astemizole, chlorpheniramine, fexofenadine, triamcinolone, diphenhydramine, and others.
In terms of geography, the report segments the market into Asia Pacific, Europe, North America, and Rest of the World (RoW). Amongst these, systemic lupus erythematosus is more common in Australia and Europe than in North America. In North America, this disease is more common amongst Asians, Hispanics, and Native Americans.
As stated in the report, the prime players operating in the market for hypersensitivity are Admac Pharma Ltd., Cadila Pharmaceuticals Ltd., DWD Pharmaceuticals Ltd, Dr. Reddy Laboratories Ltd, Panacea Biotec Ltd, Cipla Limited, Glenmark Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd., and GlaxoSmithKline Pharmaceuticals, among others.
Full Research Report on Global Hypersensitivity Market with detailed figures and segmentation at: http://www.transparencymarketresearch.com/hypersensitivity-market.html
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.